Evidence & concentration worksheet · Longevity & Mitochondrial Health
NAD+ 500 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
Nicotinamide adenine dinucleotide (NAD+) is a nucleotide-derived cellular coenzyme, not a peptide. It participates in redox reactions and enzyme signaling. Essential biology does not by itself show that intravenous NAD+ improves energy, cognition, addiction, longevity, recovery, or wellness.
Benefits & side effects
A 2019 pilot followed the NAD+ metabolome during a six-hour intravenous infusion; it was designed around metabolism and tolerability, not controlled proof of clinical benefit.[1] A 2026 retrospective real-world pilot compared infusion tolerability rather than establishing efficacy.[2] Human studies of oral precursors such as nicotinamide riboside or nicotinamide mononucleotide test different substances and routes and cannot validate IV NAD+ clinic claims.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- Frontiers in Aging Neuroscience — Pilot metabolome study during a six-hour intravenous NAD+ infusion (2019)
- Frontiers in Aging — Retrospective tolerability pilot of intravenous NAD+ and nicotinamide riboside (2026)
- U.S. FDA — Understanding the risks of compounded drugs (2026)
Other vial sizes